Evidence map›Paper›PMID 33014392›Full record

ArticleNeuro-oncology practice2020

Antidepressant drug use in glioblastoma patients: an epidemiological view.

Dorothee Gramatzki, James Louis Rogers, Marian Christoph Neidert, Caroline Hertler, Emilie Le Rhun, Patrick Roth, Michael Weller

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Dorothee GramatzkiDepartment of Neurology & Brain Tumor Center, Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland.
James Louis RogersDepartment of Neurology & Brain Tumor Center, Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland.
Marian Christoph NeidertDepartment of Neurosurgery, Clinical Neuroscience Center, University Hospital Zurich and University of Zurich, Switzerland.
Caroline HertlerDepartment of Neurology & Brain Tumor Center, Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland.
Emilie Le RhunDepartment of Neurology & Brain Tumor Center, Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland.
Patrick RothDepartment of Neurology & Brain Tumor Center, Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland.
Michael WellerDepartment of Neurology & Brain Tumor Center, Clinical Neuroscience Center, University Hospital and University of Zurich, Switzerland.ORCID 0000-0002-1748-174X
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntidepressant drugs have shown antitumor activity in preclinical glioblastoma studies. Antidepressant drug use, as well as its association with survival, in glioblastoma patients has not been well characterized on a population level.

methodsPatient characteristics, including the frequency of antidepressant drug use, were assessed in a glioblastoma cohort diagnosed in a 10-year time frame between 2005 and 2014 in the Canton of Zurich, Switzerland. Cox proportional hazards regression models were applied for multivariate analysis. Kaplan-Meier survival curves were used to estimate overall survival (OS) data and the log-rank test was performed for comparisons.

resultsA total of 404 patients with isocitrate dehydrogenase wild-type glioblastoma were included in this study. Sixty-five patients (16.1%) took antidepressant drugs at some point during the disease course. Patients were most commonly prescribed selective serotonin reuptake inhibitors at any time (N = 46, 70.8%). Nineteen patients (29.2%) were on antidepressant drugs at the time of their tumor diagnosis. No differences were observed in OS between those patients who had taken antidepressants at some point in their disease course and those who had not (

conclusionsThis signal-seeking study does not support the hypothesis that antidepressants have antitumor efficacy in glioblastoma on a population level.

Indexed as

antidepressantsdepressionepidemiologyglioblastomasurvival

Identifiers

PMID33014392
PMCPMC7516105
OpenAlexW3019559710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.